Xie, Hao http://orcid.org/0000-0002-9640-4055
Yin, Jun
Shah, Manisha H.
Menefee, Michael E.
Bible, Keith C.
Reidy-Lagunes, Diane
Kane, Madeleine A.
Quinn, David I.
Gandara, David R.
Erlichman, Charles
Adjei, Alex A.
Funding for this research was provided by:
phase 2 consortium through NCI (N01 CM17104)
Article History
Received: 7 March 2019
Accepted: 22 May 2019
First Online: 6 June 2019
Compliance with ethical standards
:
: Hao Xie declares that he has no conflict of interest. Jun Yin declares that she has no conflict of interest. Manisha H. Shah declares that she has no conflict of interest related to AT-101 except research funding from Bristol-Myers Squibb for a clinical trial in last 2 years. Michael E. Menefee declares that he has no conflict of interest. Keith C. Bible declares that he has no conflict of interest. Diane Reidy-Lagunes declares that she receives research funds from Novartis, Ipsen, and Merck, and is on the advisory board for Novartis, Ipsen, AAA, and Lexicon. Madeleine A. Kane declares that she has no conflict of interest. David I. Quinn declares that he has no conflict of interest. David R. Gandara declares that he has no conflict of interest. Charles Erlichman declares that he has no conflict of interest. Alex A. Adjei declares that he has no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.